The Comparison of Hemostatic Effects of Recombinant Activated Factor VII (rFVIIa) in Thrombocytopenic Patients (pts) and Hemophilia Pts with Inhibitors

被引：0
|
作者：
Galstian, Gennadii M. [1 ]
Kolosova, Irina V. [1 ]
Gemdzhian, Eduard [2 ]
Zorenko, Vladimir Yu. [3 ]
Polyanskaya, Tatyana A. [4 ]
Orel, Elena B. [5 ]
Savchenko, Valeri G. [6 ]
机构：
[1] Natl Res Ctr Hematol, ICU, Moscow, Russia
[2] Natl Res Ctr Hematol, Biostat, Moscow, Russia
[3] Natl Res Sci Ctr Hematol, Moscow, Russia
[4] Natl Res Sci Ctr Hematol, Dept Orthoped Surg, Moscow, Russia
[5] Natl Res Ctr Hematol, Lab Clin Coagulol, Moscow, Russia
[6] Natl Res Ctr Hematol, Moscow, Russia
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Home treatment of haemarthrosis with activated recombinant factor VII (RFVIIA) in haemophilia A and B patients with inhibitors: a prospective observational study
    Belhani, M. F.
    Khalifa, H. Hadj
    Wali, Y. A. S.
    Alzoebie, A.
    Saad, H. A.
    El Feegoun, S. Benchikh
    [J]. HAEMOPHILIA, 2013, 19 : 43 - 44
  • [32] Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)
    Tiede, A.
    Friedrich, U.
    Stenmo, C.
    Allen, G.
    Giangrande, P.
    Goudemand, J.
    Hay, C.
    Holmstrom, M.
    Klamroth, R.
    Lethagen, S.
    McKenzie, S.
    Miesbach, W.
    Negrier, C.
    Yuste, V. J.
    Berntorp, E.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (06) : 1191 - 1199
  • [33] Prophylaxis with factor VII activated in patients with severe hemophilia and inhibitors in Colombia
    Escobar-Gonzalez, A. F.
    Duque-Zapata, N.
    Vasquez, M.
    Orozco, C.
    Donado, J.
    [J]. HAEMOPHILIA, 2019, 25 : 41 - 42
  • [34] Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
    Brackmann, HH
    Effenberger, W
    Hess, L
    Schwaab, R
    Oldenburg, J
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 1998, 61 : 18 - 23
  • [35] Recombinant activated factor VII prophylactic treatment for intracranial hemorrhage in a hemophilia patient with inhibitors
    Martinez, M.
    Costa, M. A.
    Fernandez, R.
    Schuttenberg, V
    Alba, L.
    Cuello, F.
    Aznar, M.
    Formisano, S.
    Fynn, A.
    Arguello, S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1136 - 1136
  • [36] Severe obstetric bleeding treated with recombinant activated factor VII (rFVIIa)
    Segal, S
    Shemesh, IY
    Blumental, R
    Yoffe, B
    Laufer, N
    Ezra, Y
    Levy, I
    Mazor, M
    Martinowitz, U
    [J]. 2ND WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY, 2001, : 43 - 46
  • [37] Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
    Aggarwal A.
    Malkovska V.
    Catlett J.P.
    Alcorn K.
    [J]. Thrombosis Journal, 2 (1)
  • [38] Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development
    Jurlander, B
    Thim, L
    Klausen, NK
    Persson, E
    Kjalke, M
    Rexen, P
    Jorgensen, TB
    Ostergaard, PB
    Erhardtsen, E
    Bjorn, SE
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (04): : 373 - 383
  • [39] Control of a persistent obstetric haemorrhage with activated recombinant factor VII (rFVIIA)
    Jakobsen, DJ
    Shemesh, IY
    Boksenbojm, PM
    Blumenntal, R
    Segal, S
    Yoffe, B
    Martinovitz, U
    [J]. INTENSIVE CARE MEDICINE, 2001, 27 : S173 - S173
  • [40] Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials
    Caldwell, SH
    Chang, C
    Macik, BG
    [J]. HEPATOLOGY, 2004, 39 (03) : 592 - 598
12345